Skip to main content
Clinical Trials/NCT01263977
NCT01263977
Completed
N/A

A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock

Claudia Spies1 site in 1 country60 target enrollmentDecember 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
Septic Shock
Sponsor
Claudia Spies
Enrollment
60
Locations
1
Primary Endpoint
Duration of septic shock
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Septic shock and multi-organ failure are among the most frequent causes of death in the ICU.

Patients with septic shock require early implementation of hemodynamic therapy to keep the duration of shock state and with it microcirculatory disturbances as short as possible. In the septic shock guidelines by the american association SCCM the diagnosis of volume status is based on filling pressures, like CVP. Some studies show, that the CVP depends not only on the intravascular volume, but also on the right ventricular compliance, pulmonary vascular resistance as well as intrathoracic pressure. The aim of the Study is to evaluate if the duration of septic shock can be reduced through algorithm driven volume therapy orientated to thermodilution based volume parameters (GEDI and ELWI)

Registry
clinicaltrials.gov
Start Date
December 2010
End Date
May 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Claudia Spies

Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charite University, Berlin, Germany

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • Informed consent from patient, authorized proxy, carer
  • In women of child bearing age, effective contraceptive use with a known failure rate of \<1 %
  • Clinical verification of infection (≥ 48 hours possible), with at least one criteria from a - d required:
  • Proof of pathological microorganism in blood, sputum, urine or normally sterile body tissues
  • Identifiable focus (e.g. purulent sputum or wound secretion, perforated gut)
  • Identification of granulocytes in normally sterile tissue
  • Clinical suspicion of infection without identification of pathogens or micro-organisms (e.g. new pulmonary infiltrates on chest x-ray, treated pneumonia, purpura fulminants, necrotizing fasciitis)
  • Confirmation of SIRS (≥ 48 hours possible), with at least 2 criteria from a-d required:
  • Fever (≥38 °C) or Hypothermia (≤ 36 °C)
  • Tachycardia (≥ 90/min)

Exclusion Criteria

  • Therapy limited (DNR-Order)
  • Patient moribund
  • Pregnancy (positive pregnancy test in women of child bearing age)
  • Breast feeding women
  • Age \< 18 years
  • Patients active treatment for congestive heart failure with Ejection fraction \< 30% and/or NYHA Class IV congestive heart failure
  • Severe peripheral Arterial Vascular Occlusion Disease ≥ 2b after Fontaine
  • Patients with Glasgow Coma Score ≤ 8 at the time of admission and prior to the administration of medications such as sedatives
  • Patients with TNM stage 4 solid tumors, hematologic malignancies with high tumor burden, CNS tumors (WHO stage 4)
  • Patients who are likely to die within days for diseases or conditions other than catecholamine-dependent shock

Outcomes

Primary Outcomes

Duration of septic shock

Time Frame: 6 months

septic shock is defined as sepsis with mean arterial pressure (MAP) \<65mmHg or systolic arterial pressure (SAP) \<90mmHg or the need for vasopressors to support the MAP \>/= 65 mmHg or the SAP \>/= 90 mmHg

Secondary Outcomes

  • 90 and 180 days mortality(max 180 days)
  • Intensive care mortality(max 28 days)
  • Frequency of arterial hypoperfusion in the extremity of the thermodilution(max. 28 days)
  • 28 day mortality(max 28 Tage)

Study Sites (1)

Loading locations...

Similar Trials